-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Kymera Therapeutics, Raises Price Target to $120

Benzinga·12/09/2025 17:32:32
Listen to the news
Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $67 to $120.